Visible Particles, Drug Shortages, DSCSA Spotlighted In CDER’s 2020 Quality/GMP Guidance Agenda
Executive Summary
The US FDA plans to issue new guidance this year on visible particle inspections, drug shortage risk management plans, and several guidances related to DSCSA implementation, one on identifying trading partners and the other on establishing verifications systems.